GemVax Applies for Phase 3 Clinical Trial of Alzheimer's Disease Treatment
[Asia Economy Reporter Ji Yeon-jin] GemVax announced on the 27th that it has applied for approval of the Phase 3 clinical trial plan for GV1001, an Alzheimer's disease treatment, in South Korea.
Hot Picks Today
"Only Two Per Person" Garbage Bag Crisis Was Just Yesterday... Japan Also Faces Shortage Anxiety
- "Samsung Electronics Employee with 100 Million Won Salary Receiving 600 Million Won Bonus... Estimated Tax Revealed"
- Lived as Family for Over 30 Years... Daughter-in-Law Cast Aside After Husband's Death
- 'Will Demand Finally Decline Due to High Prices?'... "I'll Just Enjoy Nearby Trips" as Japan and China See a Surge
- "Wore It Once, Then This? White Spots All Over 4.15 Million Won Prada Jacket... 'Full Refund Ordered'"
The company stated, "There is a possibility that the clinical trial and product approval process may yield results that do not meet expectations, and accordingly, the company may change or abandon its commercialization plans. Investors are advised to carefully consider the disclosed investment risks comprehensively through timely disclosures and business reports before making investment decisions."
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
